Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2016150341 - POLYSACCHARIDE-POLYAMINE COPOLYMER AND USE THEREOF IN REDUCING URIC ACID CONCENTRATION IN PLASMA

Publication Number WO/2016/150341
Publication Date 29.09.2016
International Application No. PCT/CN2016/076715
International Filing Date 18.03.2016
IPC
C08B 37/00 2006.01
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
BPOLYSACCHARIDES; DERIVATIVES THEREOF
37Preparation of polysaccharides not provided for in groups C08B1/-C08B35/110; Derivatives thereof
CPC
A61K 31/738
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
738Cross-linked polysaccharides
A61K 31/785
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
74Synthetic polymeric materials
785Polymers containing nitrogen
A61K 9/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
A61P 7/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
B01J 20/264
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
20Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
22comprising organic material
26Synthetic macromolecular compounds
264derived from different types of monomers, e.g. linear or branched copolymers, block copolymers, graft copolymers
B01J 20/267
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
20Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
22comprising organic material
26Synthetic macromolecular compounds
265modified or post-treated polymers
267Cross-linked polymers
Applicants
  • 杨达志 YANG, Dazhi [US]/[CN]
Inventors
  • 杨达志 YANG, Dazhi
Agents
  • 北京市柳沈律师事务所 LIU, SHEN & ASSOCIATES
Priority Data
62/136,22020.03.2015US
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) POLYSACCHARIDE-POLYAMINE COPOLYMER AND USE THEREOF IN REDUCING URIC ACID CONCENTRATION IN PLASMA
(FR) COPOLYMÈRE DE POLYSACCHARIDE-POLYAMINE ET SON UTILISATION DANS LA RÉDUCTION DE LA CONCENTRATION PLASMATIQUE DE L’ACIDE URIQUE
(ZH) 多糖-聚氨共聚物及其在降低血浆中尿酸浓度的应用
Abstract
(EN)
Disclosed is a pharmaceutical composition for treating hyperuricemia (HUA). The pharmaceutical composition comprises a polysaccharide-polyamine copolymer and a pharmaceutically acceptable salt thereof as active ingredients. The polysaccharide-polyamine copolymer is formed by copolymerization of the following two parts: a selectively oxidized polysaccharide with 2,3-dialdehydo, and a polyamine with an amino functional group; the polyamine with an amino functional group and the selectively oxidized polysaccharide with 2,3-dialdehydo can form a net structure by means of covalent crosslinking, resulting in a hydrogel with an amino functional group or a granular polysaccharide-polyamine copolymer, wherein the amino functional group in the hydrogel with an amino functional group or the granular polysaccharide-polyamine copolymer can be protonated so as to form a cationic copolymer of a three-dimensional network structure having a protonated site, and the nitrogen content of the cationic copolymer and the nitrogen content of the polysaccharide-polyamine copolymer are above 12.3 wt%, and both the cationic copolymer and the polysaccharide-polyamine copolymer are water-insoluble.
(FR)
La présente invention concerne une composition pharmaceutique de traitement de l'hyperuricémie (HUA). La composition pharmaceutique comprend un copolymère de polysaccharide-polyamine et son sel pharmaceutiquement acceptable comme ingrédients actifs. Le copolymère de polysaccharide-polyamine est formé par copolymérisation des deux parties suivantes : un polysaccharide sélectivement oxydé avec un groupe 2,3-dialdéhydo, et une polyamine avec un groupe fonctionnel amino ; la polyamine avec un groupe fonctionnel amino et le polysaccharide sélectivement oxydé avec un groupe 2,3-dialdéhydo peuvent former une structure en filet par réticulation covalente, résultant en un hydrogel avec un groupe fonctionnel amino ou un copolymère de polysaccharide-polyamine granuleux, où le groupe fonctionnel amino dans l'hydrogel avec un groupe fonctionnel amino ou le copolymère de polysaccharide-polyamine granuleux peut être protoné afin de former un copolymère cationique d'une structure tridimensionnelle en réseau ayant un site protoné, et la teneur en azote du copolymère cationique et la teneur en azote du copolymère de polysaccharide-polyamine se situent au-dessus de 12,3 % en pds, et à la fois le copolymère cationique et le copolymère de polysaccharide-polyamine sont insolubles dans l'eau.
(ZH)
用于治疗高尿酸血症的药物组合物,药物组合物包括作为活性成分的多糖-聚胺共聚物及其药学上可接受的盐,多糖-聚胺共聚物由以下两部分共聚形成:具有2,3-二醛基的被选择性氧化的多糖,和具有胺基功能团的聚胺;具有胺基功能团的聚胺与所述具有2,3-二醛基的被选择性氧化的多糖共价交联形成网状结构,得到具有胺基功能团的水凝胶或颗粒状的多糖-聚胺共聚物,具有胺基功能团的水凝胶或颗粒状的多糖-聚胺共聚物中的胺基功能团可被质子化而形成具有质子化位点的三维网状结构阳离子共聚物,阳离子共聚物的氮含量和所述多糖-聚胺共聚物的氮含量在12.3wt%以上,阳离子共聚物和所述多糖-聚胺共聚物均不溶于水。
Also published as
Latest bibliographic data on file with the International Bureau